Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations
โ Scribed by J.W.B. de Groot; I. Plaza Menacho; H. Schepers; L.J. Drenth-Diephuis; J. Osinga; J. Th. M. Plukker; Th. P. Links; B.J.L. Eggen; R.M.W. Hofstra
- Book ID
- 113920290
- Publisher
- Elsevier Science
- Year
- 2006
- Tongue
- English
- Weight
- 354 KB
- Volume
- 139
- Category
- Article
- ISSN
- 0039-6060
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Communicated by B w e A.J. Pondei Multiple endocrine neoplasia type 2 [MEN 21 is an autosomal dominant cancer syndrome with two subtypes, 2A and 2B. MEN 2A and medullary thyroid cancer [MTC] are caused by >25 different point mutations in exons 10, 11, and 13 of the RET proto-oncogene, whereas MEN 2B
Communicated by Kenneth K. Kidd Gennline missense mutations within the coding region of the RET proto-oncogene have recently been described in patients with the dominantly inherited cancer syndromes, multiple endocrine neoplasia type 2a (MEN 2a) and familial medullary thyroid carcinoma (FMTC). To da